Document Detail


Hypoxia-Induced increase in FDG uptake in MCF7 cells.
MedLine Citation:
PMID:  11197971     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recent clinical data indicate that tumor hypoxia negatively affects the treatment outcome of both radiotherapy and surgery in various cancers, emphasizing the need for noninvasive detection of tumor hypoxia. Several studies have shown an increased uptake of FDG in hypoxic regions of xenografts, suggesting the use of PET with FDG as a potential technique. In this study, we examine the mechanism underlying the hypoxia-induced increase of FDG uptake in the human breast carcinoma cell line MCF7. METHODS: The uptake of 3H-FDG into MCF7 cells was determined after incubation under hypoxic (0% oxygen) or normoxic conditions, with or without redox agents, for varying time periods. In addition, the effects of the redox agents on the glucose transporter activity and the hexokinase activity were determined independently, and the effects of hypoxia on glucose transporter protein and hexokinase levels were assessed. RESULTS: A more than twofold increase (2.53 +/- 0.79; P < 0.005) in 3H-FDG uptake was observed under hypoxic conditions, but no changes in the cellular levels of glucose transporter proteins or hexokinase were observed. A reducing agent, dithiothreitol (DTT), also caused an increase in 3H-FDG uptake but failed to affect uptake under hypoxic conditions. This indicates that the mechanisms by which hypoxia and DTT affect 3H-FDG uptake might be the same. The oxidizing agent p-chloromercuribenzenesulfonic acid (pCMBS) had no effect on 3H-FDG uptake under normoxic conditions but counteracted the effect of hypoxia. DTT caused an increase in glucose transporter activity, whereas it had no effect on hexokinase activity. pCMBS had no effect on either glucose transporter activity or hexokinase activity. CONCLUSION: The hypoxia-induced increase in 3H-FDG uptake in MCF7 cells is the result, in part, of an increase in glucose transporter activity resulting from the modification (reduction) of thiol group(s) in the glucose transport protein(s). Modulation of hexokinase activity is probably not involved in the hypoxia-induced increase in 3H-FDG uptake in these cells.
Authors:
P Burgman; J A Odonoghue; J L Humm; C C Ling
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Journal of nuclear medicine : official publication, Society of Nuclear Medicine     Volume:  42     ISSN:  0161-5505     ISO Abbreviation:  J. Nucl. Med.     Publication Date:  2001 Jan 
Date Detail:
Created Date:  2001-01-22     Completed Date:  2001-02-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0217410     Medline TA:  J Nucl Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  170-5     Citation Subset:  IM    
Affiliation:
Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
4-Chloromercuribenzenesulfonate / pharmacology
Breast Neoplasms / metabolism*
Cell Hypoxia
Cell Line
Dithiothreitol / pharmacology
Female
Fluorodeoxyglucose F18 / pharmacokinetics*
Hexokinase / metabolism
Humans
Monosaccharide Transport Proteins / metabolism
Tritium
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/Monosaccharide Transport Proteins; 10028-17-8/Tritium; 3483-12-3/Dithiothreitol; 554-77-8/4-Chloromercuribenzenesulfonate; 63503-12-8/Fluorodeoxyglucose F18; EC 2.7.1.1/Hexokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Paclitaxel-Based chemotherapy for non-small cell lung cancer: predicting the response with 99mTc-tet...
Next Document:  Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis.